Mechanism of Action
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and…
Clinical Trials (5)
OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Loss of Exclusivity
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 6515117 | Oct 4, 2025Expired | SubstanceProduct | U-493 |
| 6515117*PED | Apr 4, 2026 | — | |
| 8329648 | Aug 18, 2026 | U-2213 | |
| 8906851 | Aug 18, 2026 | U-2139 | |
| 8906851*PED | Feb 18, 2027 | — |